Lataa...
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
Endogenous costimulatory molecules on T cells such as 4-1BB (CD137) can be leveraged for cancer immunotherapy. Systemic administration of agonistic anti–4-1BB antibodies, although effective preclinically, has not advanced to phase 3 trials because they have been hampered by both dependency on Fcγ re...
Tallennettuna:
| Julkaisussa: | Sci Transl Med |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7181714/ https://ncbi.nlm.nih.gov/pubmed/31189721 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aav5989 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|